Results overview: Found 2 records in 0.04 seconds.
Articles, 2 records found
Articles 2 records found  
1.
7 p, 820.3 KB Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation / Stein, A. S. (Gehr Family Center for Leukemia Research. City of Hope) ; Kantarjian, H. (The University of Texas M.D. Anderson Cancer Center) ; Gökbuget, N. (Department of Medicine II. Goethe University) ; Bargou, R. C. (Comprehensive Cancer Center Mainfranken. University Hospital Würzburg) ; Litzow, Mark R (Mayo Clinic) ; Rambaldi, Alessandro (Department of Oncology and Hemato-Oncology. University of Milan and Azienda Pope John XXIII Hospital) ; Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Zhang, A. (Amgen Inc.) ; Zimmerman, Z. (Amgen Inc.) ; Zugmaier, Gerhard (Amgen Research Munich) ; Topp, M. S. (Medical Clinic and Polyclinic II. University Hospital Würzburg) ; Universitat Autònoma de Barcelona
Patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) following allogeneic hematopoietic stem cell transplantation (alloHSCT) have a poor prognosis, and alternative therapies are needed for this patient population. [...]
2019 - 10.1016/j.bbmt.2019.04.010
Biology of Blood and Marrow Transplantation, Vol. 25 Núm. 8 (august 2019) , p. 1498-1504  
2.
6 p, 186.9 KB Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab / Topp, Max S. (Universitätsklinikum Würzburg) ; Gökbuget, Nicola (Goethe University) ; Zugmaier, Gerhard (Amgen GmbH) ; Stein, Anthony S. (Gehr Family Center for Leukemia Research. City of Hope) ; Dombret, Hervé (Saint Louis Hospital. University of Paris) ; Chen, Yuqi (Amgen. Inc) ; Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Bargou, Ralf C. (Comprehensive Cancer Center Mainfranken. University Hospital Würzburg) ; Horst, Heinz-August (Universitätsklinikum Schleswig-Holstein (Alemanya)) ; Kantarjian, H. M. (The University of Texas MD Anderson Cancer Center) ; Universitat Autònoma de Barcelona
Background: Blinatumomab is a CD19 BiTE (bispecific T-cell engager) immuno-oncology therapy that mediates the lysis of cells expressing CD19. Methods: A pooled analysis of long-term follow-up data from 2 phase 2 studies that evaluated blinatumomab in heavily pretreated adults with Philadelphia chromosome-negative, relapsed/refractory B-cell precursor acute lymphoblastic leukemia was conducted. [...]
2021 - 10.1002/cncr.33298
Cancer, Vol. 127 Núm. 4 (15 2021) , p. 554-559  

See also: similar author names
1 Topp, M.
1 Topp, M. S.
1 Topp, Max S.
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.